



Genocea Biosciences  
Investor Relations Department  
100 Acom Park Drive, 5th Floor  
Cambridge, MA 02140  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

#### NASDAQ: GNCA


Last Trade:	1.46
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.13 - 7.29
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Sep 25, 2017*  
[Genocea Announces Strategic Shift to Immuno-oncology and the Development of Neoantigen Cancer Vaccines](#)
- Sep 20, 2017*  
[Genocea to Present at Cantor Fitzgerald Healthcare Conference](#)
- Aug 9, 2017*  
[Genocea Biosciences Reports Second Quarter 2017 Financial Results](#)
- Jul 28, 2017*  
[Genocea Biosciences to Highlight GEN-003 Clinical Data at the 42nd Annual International Herpesvirus Workshop](#)
- Jul 24, 2017*  
[Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes](#)

## Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 17, 2017*  
[Annual Report \(10-K\)](#)
- Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*  
[Quarterly Report \(10-Q\)](#)